Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy

Research output: Contribution to journalArticle


The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.

Original languageEnglish
Pages (from-to)285-289
Number of pages5
JournalObstetrics and Gynecology Science
Issue number4
StatePublished - 1 Jul 2019



  • Drug therapy
  • Infusions, parenteral
  • Neoplasm recurrence, local
  • Ovarian neoplasms
  • Peritoneal neoplasms

Cite this